Shilpa Pharma Lifesciences Limited, a active public limited company, was established on 08 May 2020 in Raichur, Karnataka, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U24100KA2020PLC134081. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹20.00 Cr and a paid-up capital of ₹10.00 Cr.
Formerly known as Shilpa Corporate Holdings Private Limited, Shilpa Pharma Lifesciences Private Limited. Employing 1,200 professional, Its leadership includes Ramakant Innani (Director), Anita Bandyopadhyay (Director), Keshav Bhutada (Director). Past directors included Anita Bandyopadhyay, Keshav Bhutada, Vishnukanth Chaturbhuj Bhutada. It holds ₹663.25 Cr open charges and ₹598.00 Cr settled loans. Its latest AGM occurred on 16 September 2024, with the balance sheet filed on 31 March 2024. It is based at 12-6-214/A-1, Shilpa House, Hyderabad Road,, Raichur, Karnataka, 584135.
U24100KA2020PLC134081
134081
08 May 2020
₹20.00 Cr
₹10.00 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Shilpa Pharma Lifesciences Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramakant Innani | Director | 08 May 2020 | Current |
| Anita Bandyopadhyay | Director | 12 Aug 2022 | Current |
| Keshav Bhutada | Director | 09 Mar 2022 | Current |
| Vishnukanth Chaturbhuj Bhutada | Managing Director | 08 May 2020 | Current |
| Kalakota Reddy Sharath | Director | 29 Mar 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 27 Sep 2022 | Past |
| Pramod Abcsdd | Director | 18 Jun 2024 | Past |
| Pramod Abcsdd | Director | 12 Aug 2022 | Past |
| Pramod Abcsdd | Ceo | 24 May 2025 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Shilpa Pharma Lifesciences Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1229.81% decrease in profit. The company's net worth Soared by an impressive increase of 10.4%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Shilpa Pharma Lifesciences had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹6,632,500,000.00
₹5,980,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Jul 2025 | Others | ₹75.00 Cr | Open |
| 16 May 2025 | Others | ₹88.00 Cr | Open |
| 08 Jan 2025 | Others | ₹249.75 Cr | Open |
| 27 Feb 2023 | Others | ₹5.00 M | Open |
| 27 Oct 2022 | Axis Bank Limited | ₹150.00 Cr | Open |
Explore comprehensive loan charge details -
Shilpa Pharma Lifesciences has a workforce of 1200 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Shilpa Pharma Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shilpa Pharma Lifesciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge registered on 30 Mar 2024 via Charge ID 100928819 with Others was fully satisfied on 03 Sep 2025. was completed.
Progress on A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101144036 was registered on 31 Jul 2025. was documented.
Keshav Bhutada was appointed as a Ceo was appointed as a Ceo on 20 Jun 2025 & has been associated with this company since 5 months 14 days . was recorded as a recent event.
A charge with Others amounted to Rs. 88.00 Cr with Charge ID 101106775 was registered on 16 May 2025. was recorded as a recent event.
The activity A charge with Others of Rs. 75.00 Cr registered on 30 Mar 2024 with Charge ID 100928819 was modified on 28 Feb 2025. was completed.
A charge registered on 04 Aug 2023 via Charge ID 100917993 with Others was fully satisfied on 24 Feb 2025. was recorded as a recent event.
"The inspection concluded with two observations. There were no repeat observations or Data Integrity (DI) related observations," the company added. .
"We have received Form 483 with five observations, with no repeat observations and any data integrity observations. The observations are mostly procedural in nature," the Shilpa Medicare... .
Shilpa Medicare gets USFDA approval for Irinotecan injection to treat cancer. Yay! It's used for colon or rectum cancer and the US market is worth $18 million. #winning #cancerfighter.
The CIN of Shilpa Pharma Lifesciences Limited is U24100KA2020PLC134081.
Shilpa Pharma Lifesciences Limited is headquartered at 12-6-214/A-1, Shilpa House, Hyderabad Road,, Raichur, Karnataka, 584135.
Shilpa Pharma Lifesciences Limited was incorporated on 08 May 2020.
The current directors of Shilpa Pharma Lifesciences Limited are
The primary industry of Shilpa Pharma Lifesciences Limited is Manufacturing.
Shilpa Pharma Lifesciences Limited is unlisted.
The authorized capital of Shilpa Pharma Lifesciences Limited is ₹20.00 Cr, and the paid-up capital is ₹10.00 Cr.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX